Nockowitz v. Janssen Pharmaceuticals, Inc., et al

Filing 18

Certified Conditional Transfer Order (CTO-1). Signed by MDL Panel on 12/20/16. (Copies have been distributed pursuant to the NEF - MMM)

Case MDL No. 2750 Document 157 Filed 12/19/16 Page 1 of 3

UNITED STATES JUDICIAL PANEL
on
MULTIDISTRICT LITIGATION

IN RE: INVOKANA (CANAGLIFLOZIN)
PRODUCTS LIABILITY LITIGATION

MDL No. 2750

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO --1)

On December 7, 2016, the Panel transferred 18 civil action(s) to the United States District Court for
the District of New Jersey for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C.
§ 1407. See _F.Supp.3d_ (J.P.M.L. 2016). Since that time, no additional action(s) have been
transferred to the District of New Jersey. With the consent of that court, all such actions have been
assigned to the Honorable Brian R. Martinotti.
It appears that the action(s) on this conditional transfer order involve questions of fact that are
common to the actions previously transferred to the District of New Jersey and assigned to Judge
Martinotti.
Pursuant to Rule 7 .1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict
Litigntion, the action(s) on the attached schedule are transferred under 28 U.S.C. §-1407 to the
District of New Jersey for the reasons stated in the order of December 7, 2016, and, with the consent
of that court, assigned to the Honorable Brian R. Martinotti.
This order does not become effective until it is filed in the Office of the Clerk of the United States
District Court for the District of New Jersey. The transmittal of this order to said Clerk shall be
stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the
Panel within this 7-day period, the stay will be continued until further order of the Panel.
Inasmuch as no objection i_s
pending at this time, the
stay is lifted.

IDec 19, 2016 j
CLERK'S OFFICE
UNITED STATES
JUDICIAL PANa ON
MULTIOiSTRICT LITIGATION

FOR THE PANEL:

~~Jeffery N. Luthi
Clerk of the Panel

Case MDL No. 2750 Document 157 Filed 12/19/16 Page 2 of 3

IN RE: INVOKANA (CANAGLIFLOZIN)
PRODUCTS LIABlLITY LITIGATION

MDL No. 2750

SCHEDULE CT0-1 - TAG-ALONG ACTIONS

C.A.NO.

CASE CAPTION

CALIFORNIA CENTRAL
CAC

5

16-02020

Lois Mercado v. Janssen Research and Development,
LLC et al

16-00281

KAMPE v. JANSSEN PHARMACEUTICALS INC

16-01406

Cape v. Janssen Ortho LLC et al

16-09441

Faedtke v. Janssen Pharmaceuticals, Inc.

16-01140

Klein v. Janssen Pharmaceuticals, Inc.

16-00065

Moore et al v. Janssen Research & Development, LLC
et al

16-00658

Tindle v. Janssen Pharmaceuticals, Inc. et al

16-16678

Vetter v. Janssen Pharmaceuticals, Inc. et al

FLORIDA NORTHERN
FLN

5

ILLINOIS CENTRAL
ILC

1

ILLINOIS NORTHERN
ILN

1

ILLINOIS SOUTHERN
ILS

3

KENTUCKY EASTERN
KYE

0

KENTUCKY WESTERN

KYW

3

LOUISIANA EASTERN

LAE

2

MISSOURI EASTERN
4

16 Q1'7Q7

Gntaas Williaffts et al v. Ja:Mse:e: Pfta.rmeeemieals, I:ae.
et-el

Opposed 12/19/16

Case MDL No. 2750 Document 157 Filed 12/19/16 Page 3 of 3
MOE

4

16--01766

Seamon v. Janssen Pharmaceuticals, Inc. et al

2

16-02417

Nockowitz v. Janssen Pharmaceuticals, Inc., et al

16-02476

Carlson et al v. Janssen Pharmaceuticals, Ille.

16-00407

Ryan v. Janssen Pharmaceuticals, Inc. et al

16-03052
16-03053

Adams v. Janssen Pharmaceuticals, Inc.
Price v. Janssen Pharmaceuticals, Inc.

NEVADA
NV

OHIO NORTHERN
OHN

1

TENNESSEE EASTERN

tNE

1

TENNESSEE MIDDLE

TNM
TNM

3
3